Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q1 2026 Earnings Presentation
16 slides from Anika Therapeutics's earnings presentation, Apr 29, 2026
Slide 1: Q1 2026 Earnings Call
Q1 2026 EARNINGS CALL APRIL 29, 2026 Anika. Restore Active Living.
Slide 2: Safe Harbor Statements
SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and
Slide 3: Company Highlights
COMPANY HIGHLIGHTS STRATEGY DRIVING GROWTH, PIPELINE ADVANCEMENT AND OPERATIONAL DISCIPLINE Growth New Product Pipeline Operational Discipline • Commercial Channel grew 12% in Q1 led • Hyalofast PMA under FDA review with • Gross margin expanded more than 8 by Regenerative Solutions 20% increase time
Slide 4: Integrity Unit Sales Update
INTEGRITY UNIT SALES UPDATE Integrity Unit Sales Since Launch 700 2000 600 500 1500 400 300 1000 • US Q1 procedures increased 35% year over year, generating $1.8M in revenue 200 500 • Surgeon adoption continues to expand, with new surgeon adds 100 growing at double-digit rates month over month • New
Slide 5: Q1 2026 Financial Highlights
Q1 2026 FINANCIAL HIGHLIGHTS $M, except per share data CONTINUING OPERATIONS 1Q26 Continuing Operations Highlights Q1 Financial Results 2026 VPY • Revenue of $29.6M up 13% vs prior year driven by Commercial Channel growth and OEM Channel order Revenue $29.6 13% timing Commercial $12.6 12% • Commerci
Slide 6: Maintaining 2026 Guidance
MAINTAINING 2026 GUIDANCE $M 2021 2022 2023 2024 2025 2026 Est 1 2027 Est 1 $114 – Total Company Revenue $107 $114 $121 $120 $113 $122.5 +1%–9% Commercial Revenue +17% 4-Year CAGR • International OA Pain • Global Regenerative Solutions • US Hyalofast (2027) $53 - $58 +10-20% $36 $42 $48 +10-20% $26
Slide 7: Strategies to Deliver Shareholder Value
3 STRATEGIES TO DELIVER SHAREHOLDER VALUE • Accelerating growth driven by strong Commercial Channel momentum • Advancing a Robust New Product Pipeline with Hyalofast, Cingal, the Integrity platform, and next-generation HA technologies • Strengthening operational discipline with improved productivity
Slide 8: Non-GAAP Reconciliation and Supplemental Data
NON-GAAP RECONCILIATION AND SUPPLEMENTAL DATA 8
Slide 9: Statement of Operations
STATEMENT OF OPERATIONS ‘Anika Therapeutics, Inc. and Subsidiaries Consolidated Statements of Operations {in thousands, except per share data) (unaudited) For the Three Months Ended March 31, 2026 2025 Revenue $ we $ 2168S wer $ 26,168 Cost of Revenue 10615 11487 10615 11487 Gross Proft 18.997 14681
Slide 10: Balance Sheet
BALANCE SHEET @ ANIKA Consolidated Balance Sheets {in thousands, except per share data) (unaudited) ‘March 31, ASSETS 2026 Current assets: (Cash and cash equivalents, 41,020 ‘Accounts receivable, net 25,768 Inventories, net 22,838 Prepaid expenses and other current assets 3935 Total current assets 9
Slide 11: Cash Flow Statement
CASH FLOW STATEMENT @ ANIKA Cash flows from operating activities: Netloss Adjustments to reconcle net income to net cash provided by operating activities: Depreciation “Amortization of acquéition related intangible assets Nor-cash operating lease cost, ‘Stock-based compensation expense Deferred inco
Slide 12: Reconciliation Tables – GAAP Net Income (Loss) to Adjusted EBITDA
RECONCILIATION TABLES – GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA 12
Slide 13: Reconciliation Tables – GAAP Net Income to Adjusted Net Income
RECONCILIATION TABLES – GAAP NET INCOME TO ADJUSTED NET INCOME 13
Slide 14: Reconciliation Tables – GAAP EPS to Adjusted EPS
RECONCILIATION TABLES – GAAP EPS TO ADJUSTED EPS 14
Slide 15: Revenue by Channel
REVENUE BY CHANNEL OEM Channel ‘Commercial Channel @ ANIKA Anika Therapeutics, Inc. and Subsidiaries Revenue by Product Family (in thousands, except percentages) (unaudited) For the Three Months Ended March 31, For the Three Months Ended March 31, 2026 2025 Schange % change 2026 2025 Schange __% cha
Slide 16: @ ANIKA
@ ANIKA